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Abstract
Background:  Peptidylarginine deiminase type 4 (PAD4/PADI4) post-translationally converts
peptidylarginine to citrulline. Recent studies suggest that PADI4 represses expression of p53-regulated
genes via citrullination of histones at gene promoters.
Methods: Expression of PADI4 was investigated in various tumors and non-tumor tissues (n = 1673) as
well as in A549, SKOV3 and U937 tumor cell lines by immunohistochemistry, real-time PCR, and western
blot. Levels of PADI4 and citrullinated antithrombin (cAT) were investigated in the blood of patients with
various tumors by ELISA (n = 1121).
Results: Immunohistochemistry detected significant PADI4 expression in various malignancies including
breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells,
colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas,
uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas,
endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias,
hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and
cavernous hemangiomas of the liver. Additionally, PADI4 expression was not detected in non-tumor
tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed
tissues such as in gastritis and appendicitis. Quantitative PCR and western blot analysis showed higher
PADI4 expression in gastric adenocarcinomas, lung adenocarcinomas, hepatocellular carcinomas,
esophageal squamous cell cancers and breast cancers (n = 5 for each disease) than in the surrounding
healthy tissues. Furthermore, western blot analysis detected PADI4 expression in cultured tumor cell
lines. ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant
tumors compared to those in patients with chronic inflammation and benign tumors. This was consistent
with immunohistochemical results. Additionally, PADI4 and cAT levels were significantly associated with
higher levels of known tumor markers.
Conclusion: Our results suggest that PADI4 expression is increased in the blood and tissues of many
malignant tumors, a finding useful for further understanding of tumorigenesis.
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Background
In a process known as citrullination, peptidylarginine
deiminase type 4 (PAD4/PADI4) post-translationally con-
verts peptidylarginine to citrulline. Previously, Cuthbert et
al. had found that citrullination by PADI4 prevents
arginine methylation of histones H3 and H4 during tran-
scriptional activation of estrogen-responsive genes [1].
Further evidence has confirmed that PADI4 is significantly
associated with rheumatoid arthritis (RA), thus playing an
important role in the pathogenesis of this disease [2]. We
previously detected intense PADI4 expression in tumor
cells from various adenocarcinomas, but not in healthy
tissues [3]. We also demonstrated co-localization of
PADI4 with cytokeratin, an intermediate filament protein
that plays a role during cell differentiation and apoptosis
[3-6]. To further confirm these findings, we investigated
PADI4 expression by immunohistochemistry, real-time
PCR and western blot analysis in various benign tumors
and non-tumor inflamed tissues in the current study. Due
to the relatively low, sometimes undetectable, expression
of PADI4 in tumor tissue extracts, we performed western
blot following immunoprecipitation in the study. We also
examined PADI4 expression in cultured lung adenocarci-
noma (A549), ovarian adenocarcinoma (SKOV3), and
leukemia (U937) cell lines. Additionally, we investigated
PADI4 levels in the blood of patients with various tumors
in the present study. Since we previously detected citrulli-
nation and subsequent inactivation of antithrombin in
the plasma of RA patients [7], we also measured levels of
citrullinated antithrombin (cAT) in the blood of patients
containing various tumor types. By analyzing levels of
PADI4 and cAT, as well as the levels of known tumor
markers, we aimed to explore the pathogenic role of
PADI4 during carcinogenesis.
Methods
Immunohistochemistry
Various malignant tumors, benign tumors and non-tumor
inflamed tissues (n = 1673, see Table 1) were collected
during excision surgery at several hospitals in the Shan-
dong region of China. Tumor diagnosis was verified by
histological methods, and pathological categorization
was determined according to the World Health Organiza-
tion (WHO) classification system. All patients signed
informed consents, and this study was approved by the
ethics committee of Shandong Academy of Medical Sci-
ences.
Tissue samples were fixed in 10% neutral buffered forma-
lin and embedded in paraffin. Tissue sections were depar-
affinized and rehydrated using standard procedures. To
increase the intensity of immunostaining, the sections
were heated at 95°C for 10 min in citrate buffer (0.01 M,
pH 0.6), then incubated overnight at 4°C with anti-
PADI4 antibody. Anti-PADI4 was prepared by immuniz-
ing rabbits with the synthetic oligopeptide FGDSCYP-
SNDSRQMH, and immunospecificity was confirmed in a
previous study [3]. Immunoreactions were processed
using the UltraSensitive TM S-P Kit (Maixin-Bio, China)
according to the manufacturer's instructions, and signals
were visualized using the DAB substrate, which stains the
target protein yellow.
The intensity of immunosignals was evaluated by a previ-
ously described protocol from Denkert et al. [8]. For each
histological section, the percentage of positive cells was
scored as 0 (0%), 1 (10%), 2 (10–50%), 3 (51–80%) and
4 (> 80%), and the staining intensity was scored as 0 (neg-
ative), 1 (weak), 2 (moderate) and 3 (strong). The immu-
noreactive score (IRS) was obtained by multiplying the
percentage of positive cells and the staining intensity.
Immunohistochemical results with an IRS of 0–1 were
considered negative, 1–2 weak and 6–12 positive.
Immunoprecipitation and western blot analysis
Gastric adenocarcinomas (n = 5), lung adenocarcinomas
(n = 5), hepatocellular carcinomas (n = 4), esophageal
squamous cell cancers (n = 5), breast cancers (n = 5), and
breast fibroadenomas (n = 5) were collected during exci-
sion surgery. Normal, healthy tissues located 5 cm away
from the corresponding tumors were collected during sur-
gery for control histological examinations. Sample tissues
(200 ug) were homogenized with Cell Lysis Solution
(Sigma) and centrifuged at 16000 × g for 5 min at 4°C.
The supernatant was collected, and protein concentra-
tions were determined using the BCA Protein Assay Kit
(Pierce). Immunoprecipitation (IP) was performed using
a Protein G Immunoprecipitation Kit (Sigma) according
to the manufacturer's instructions. Briefly, an equal
amount of lysate from each sample was incubated over-
night at 4°C with the PADI4 antibody in the presence of
a Protease Inhibitor Cocktail (Sigma). Protein G beads
were added to the mixture and incubated for 2 h at 4°C.
After thorough washing, the purified PADI4 protein was
eluted with 1× Laemmli sample buffer (Sigma). IP sam-
ples (10 ul) were separated by SDS-PAGE and then trans-
ferred onto PVDF membranes using the Mini-PROTEAN 3
system (Biorad). The membranes were probed with mon-
oclonal anti-PADI4 antibody containing a recombinant
fragment of human PADI4 between residues 2–111
(Abcam), and then incubated with sheep anti-mouse IgG
conjugated to alkaline phosphatase (Sigma). Immunosig-
nals were visualized with the Protein Detector BCIP/NBT
Western Blot Kit (KPL) following the manufacturer's
instructions.
We also measured PADI4 expression in total protein
extracts from the tumor cell lines A549, SKOV3 and U937.
Preparation of protein extracts was performed as
described above.BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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ELISA
Blood samples were collected from patients with malig-
nant tumors 4–6 days prior to and after tumor excision
surgery. Blood from healthy volunteers and from patients
with benign tumors or non-tumor inflammation were
used as controls. All samples (n = 1121, see Table 2) were
collected in Monovette tubes containing 3.8% sodium cit-
rate and centrifuged at 1500 × g for 20 min. Supernatants
of anticoagulated plasma were collected and stored at -
80°C until use. Plasma samples were diluted 1:20 in 0.05
M carbonate-bicarbonate buffer (pH 9.6) and used to coat
96-well EIA/RIA microplates (Costar) overnight at 4°C.
After a brief wash with PBST (8 g NaCl, 0.2 g KCl, 1.15 g
NaHPO4 and 0.2 g KH2PO4 per liter, pH 7.4–7.6, 0.1%
Tween 20), plates were blocked with 5% non-fat dry milk
for 1 h at room temperature. Anti-PADI4 antibody
(diluted 1:4000 in PBST) was added to the plates and
incubated for 2 h at room temperature. After washing with
PBST, plates were incubated with 1:10,000 anti-rabbit IgG
conjugated to alkaline phosphatase (Sigma) for 30 min at
room temperature. Plates were then washed with PBST,
and the signal was developed by adding the Alkaline
Phosphatase Yellow (pNpp) Liquid Substrate System for
ELISA (Sigma). Absorbance at 405 nm was measured
using a spectrophotometer (Synergy HT, Bio-Tek).
Sandwich ELISA
Anti-human antithrombin monoclonal antibody
(Abcam) was diluted 1:5000 in 0.05 M carbonate-bicar-
bonate buffer (pH 9.6) and used to coat microplates over-
night at 4°C. After a brief wash with PBST, the plates were
blocked with 5% non-fat dry milk for 1 h at room temper-
Table 1: The PADI4 expression in tumors and non-tumor inflamed tissues
tissues expression no expression positivity %
breast cancer 144 6 96
breast fibroadenoma 5 72 6.5
esophageal squamous cell cancer 80 15 84.2
gastric adenocarcinoma 56 10 84.8
rodents 24 38 38.7
gastritis 20 44 31.2
leiomyosarcoma of stomach 7 38 15.6
colorectal adenocarcinoma 24 4 85.7
cholecystitis 0 20 0
appendicitis 20 4 83.3
myoma of uterus 0 60 0
endometrial hyperplasia of uterus 10 66 13.1
endometrial carcinoma 31 1 96.8
cervical polyp 0 20 0
cervicitis 0 20 0
hydatidiform mole 0 20 0
ovarian carcinoma 66 2 97
hydatidiform mole 0 20 0
teratoma 8 40 16.7
primary lymphoma 20 8 71.4
lymphadenitis 0 20 0
skin cancer 20 0 100
intradermal nevus 0 20 0
lipoma 0 20 0
hepatocellular carcinoma 20 0 100
hepatoblastoma 0 20 0
liver cirrhosis 108 52 67.5
hepatic cavernous hemangioma 0 72 0
lung adenocarcinoma 62 0 100
renal cell carcinoma 47 7 87
chondroma 20 0 100
osteosarcoma 50 1 98
bladder carcinomas 20 0 100
metastatic carcinoma 20 0 100
thyroid adenoma 0 40 0
hemangioma 0 20 0
neurofibroma 0 20 0
pleomorphic adenoma of salivary 2 22 8.3
synovitis 0 18 0BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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ature. Plasma samples diluted 1:20 in PBST were added to
the plates and incubated for 2 h at room temperature.
After washing with PBST, plates were incubated with
1:4000 rabbit anti-citrulline (Abcam) for 1 h at room tem-
perature. The anti-citrulline antibody was labeled with
alkaline phosphatase using the AP Labeling Kit (Roche)
according to the manufacturer's instructions. The plates
were then washed with PBST, and signals were detected as
described above.
Measure of tumor markers in patient blood samples
CEA levels were measured in all blood samples, AFP levels
in liver cancer samples, CA199 levels in digestive tract
tumor samples, CA125 levels in ovarian cancer samples,
CA153 levels in breast cancer samples, CYFRA21-1 levels
in lung cancer samples, and PSA levels in prostate cancer
samples. All measurements were performed in a clinical
laboratory cooperating with us.
ELISA data were collected from three independent tests.
All statistical analyses were conducted using SPSS (version
11.0). The median and range of PADI4 and cAT levels are
reported. The Mann-Whitney U-test statistically assessed
differences between the groups, and the x2 test was used to
examine the association between expression of PADI4,
cAT and several tumor markers. P values ≤ 0.05 were con-
sidered as statistically significant.
Real-Time Quantitative PCR
Total RNA was extracted using the TRIzol reagent (Invitro-
gen) from gastric adenocarcinomas (n = 5), lung adeno-
carcinomas (n = 5), hepatocellular carcinomas (n = 4),
esophageal squamous cell cancers (n = 5), breast cancers
(n = 5) and breast fibroadenomas (n = 5), as well as their
corresponding healthy tissues. Concentrations of total
RNA were determined with a spectrophotometer. Quanti-
tative PCR analyses were performed using the iCycler
Real-Time Detection System (Bio-Rad). Gene-specific
primers were designed using the PADI4 mRNA sequence
in Genbank (NM012387) and were as follows: forward 5'-
ctgtggtgttccaagacagc-3' (nt position 871–890) and reverse
5'-gcttggatgtagccgatctc-3' (nt position 1083–1102). The
TaqMan probe 5'-cccaacacccagcccccgca-3' (nt position
924–943) was labeled at the 5' end with the reporter dye
FAM (6-carboxy-fluorescein) and at the 3' end with the
quencher TAMRA (6-carboxy-teremethyl-rhodamine)
(TaKaRa). cDNA was prepared with 1 ug of total RNA
from each sample using random hexamers and reverse
transcription with the PrimeScriptTM RT-PCR Kit
(TaKaRa). A 232 bp DNA fragment was produced by 1st
strand cDNA synthesis with the above primer set, cloned
into the pGEM-T Easy Vector (Promega), and verified by
sequence analysis. Purified recombinant plasmid was seri-
ally diluted to 1×107, 1×106, 1×105, 1×104, 1×103 and
1×102 copies/ml. TaqMan real-time PCR was performed
using the PrimeScriptTM RT-PCR Kit (TaKaRa) in 25 ul of
reaction mixtures containing 12.5 ul of Premix Ex Taq, 0.5
ul of forward primer (10 uM), 0.5 ul of reverse primer (10
uM), 1 ul of TaqMan probe (3 uM), 2 ul of recombinant
plasmid or cDNA and 8.5 ul of H2O. The following opti-
mized thermal cycling program was used: denaturation at
95°C for 3 min, followed by 50 cycles of 95°C for 30 s
and 60°C for 30 s; fluorescence data were collected at the
60°C annealing and extension step. The PCR threshold
cycle (Ct), which is defined as the fractional cycle number
at which the fluorescence reaches 10 times the standard
deviation of the baseline, was determined by the iCycler
iQ software. Standard curve equations were calculated by
regression analysis of the average Ct versus the log10 of
the standard copy number. Copy numbers of PADI4
mRNA in clinical samples were calculated automatically
by the data analysis software.
Results
PADI4 expression was detected by immunohistochemis-
try in all malignant tumor types examined including
breast carcinomas, lung adenocarcinomas, hepatocellular
carcinomas, esophageal squamous cancer cells, colorectal
adenocarcinomas, renal cancer cells, ovarian adenocarci-
nomas, endometrial carcinomas, uterine adenocarcino-
mas, bladder carcinomas, chondromas, and other
metastatic carcinomas (IRS ≥ 9). Furthermore, PADI4 was
also expressed in over 40% of cells in malignant lympho-
mas (IRS ≥ 8). In contrast, no significant levels of PADI4
were detected in various benign tumors including leiomy-
omas of the stomach, uterine myomas, endometrial
hyperplasias, cervical polyps, teratomas, hydatidiform
moles, trophoblastic cell hyperplasias, hyroid adenomas,
hemangiomas, lymph hyperplasias, schwannomas, neu-
rofibromas, lipomas, and cavernous hemangiomas of the
liver (IRS: 0–1). In breast fibroadenoma, thyroid ade-
noma, and pleomorphic adenoma samples, PADI4 was
observed in the endothelial cells of capillaries and gland
structures (IRS: 1–6), both of which mainly consist of
benign tissues. PADI4 expression was not detected in
most non-tumor inflamed tissues including cholecystitis,
cervicitis and synovitis of osteoarthritis (IRS ≤ 1),
although half of gastric ulcer and acute appendicitis sam-
ples displayed smeared PADI4 immunosignals (IRS: 3–6).
In addition, more than 60% of the liver cirrhosis samples
showed PADI4 expression (IRS: 3–8). PADI4 was also
expressed in several mesenchymal cells in both tumor and
non-tumor inflamed tissues. Immunohistochemical
results are shown and listed in Figure 1 and Table 1,
respectively.
By western blot analysis, a 67 kDa band was detected in IP
extracts of gastric adenocarcinomas, lung adenocarcino-
mas, hepatocellular carcinomas, esophageal squamous
cell cancers and breast cancers as well as in their corre-BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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Immunohistochemistry showing PADI4 expression in various malignant tumors, benign tumors and non-tumor inflamed tissues Figure 1
Immunohistochemistry showing PADI4 expression in various malignant tumors, benign tumors and non-
tumor inflamed tissues. 1. breast cancer, 2. breast fibroadenoma. 3. esophageal squamous cell cancer, 4. gastric adenocarci-
noma, 5. leiomyosarcoma of stomach, 6. gastritis, 7. colorectal adenocarcinoma, 8. colorectal polyps, 9. hepatocellular carci-
noma, 10. hepatoblastoma, 11. liver cirrhosis, 12. cholecystitis, 13. endometrial carcinoma, 14. myoma of uterus, 15. 
endometrial hyperplasia of uterus, 16. cervicitis, 17. cervical polyp, 18. hydatidiform mole, 19. chondroma, 20. teratoma, 21. 
skin cancer, 22. intradermal nevus, 23. thyroid adenoma, 24. pleomorphic adenoma of salivary gland. The tissue structure of 
the section was defined by counterstaining with hematoxylin. The brown color in nevus cells was caused by pigment sediment. 
The color was also observable in the control sections without treatment of 1st or 2nd antibody. Original magnification was 
100×.BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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sponding healthy tissues (see Figure 2). Immunosignal
densities were significantly higher in malignant tissues
than in corresponding healthy tissues or in breast fibroad-
enomas. Since IP extracts were purified from equivalent
tissue weights for each sample, the density of the immu-
nosignals directly corresponded to PADI4 expression lev-
els. In addition, PADI4 was detected in total protein
extracts from A549, SKOV3 and U937 tumor cell lines.
TaqMan quantitative PCR was used to measure PADI4
transcription in tumor samples. Levels of PADI4 mRNA
were determined from standard curves and amplification
plots (based on the Ct and copy number). As cDNA tem-
plates were synthesized from an equivalent amount of
total RNA for each sample, the copy number/ug total RNA
directly corresponds to PADI4 expression levels in the tis-
sue samples. PADI4 transcripts were detected in gastric
adenocarcinomas, lung adenocarcinomas, hepatocellular
carcinomas, esophageal squamous cell cancers, breast
cancers and breast fibroadenomas as well as their corre-
sponding healthy tissues. PADI4 mRNA levels were signif-
icantly elevated in malignant tissues compared to those in
corresponding healthy tissues. The PADI4 mRNA level in
breast fibroadenomas was lower than that in breast can-
cers, but higher than that in corresponding healthy tis-
sues. TaqMan quantitative PCR results are shown in
Figure 3.
Plasma PADI4 levels of patients with malignant tumors
were measured by ELISA and compared with those with
benign and healthy controls. PADI4 levels were signifi-
cantly increased in the blood of patients with breast carci-
nomas, hepatocellular carcinomas, lung cancer,
esophageal carcinomas, gastric cancer, colon cancer, rectal
cancer, pancreatic cancer, ovarian carcinomas, renal cell
carcinomas, cervical cancer, prostate carcinomas and
bladder carcinomas (p < 0.01), but not in those with
endometrial carcinomas, uterine myomas and thyroid
carcinomas. After tumor excision surgery, PADI4 levels in
the blood decreased considerably in breast carcinomas,
hepatocellular carcinomas, lung cancer, gastric cancer,
colon cancer, rectal cancer and pancreatic cancer samples
(p < 0.05). Meanwhile, plasma PADI4 levels in patients
with chronic gastritis, chronic nephritis and cervicitis did
not considerably change, or even declined, compared to
samples from healthy control patients. However, patients
with breast fibroadenomas, thyroid adenomas, hepatitis A
and B, liver cirrhosis, pulmonitis, acute pancreatitis and
acute appendicitis had higher plasma PADI4 levels than
those of healthy controls, with some samples showing
even higher levels than that observed for patients with
malignancies. ELISA results of PADI4 are shown in Figure
4.
Plasma cAT levels of patients with malignant tumors were
measured by sandwich ELISA and compared to those with
benign tumors and healthy controls. Plasma cAT levels
were significantly elevated in most patients with malig-
nant tumors, including those with breast carcinomas,
hepatocellular carcinomas, lung carcinomas, esophageal
carcinomas, gastric cancer, colon cancer, rectal cancer,
pancreatic cancer, ovarian carcinomas, bladder carcino-
mas, uterine myomas, thyroid carcinomas and prostate
carcinomas (p < 0.01), but not in those with cervical can-
cer or endometrial carcinomas. After tumor excision sur-
gery, cAT levels in the blood declined for most
Western blot analysis of PADI4 expression in tumor cell lines, tumors and corresponding healthy tissues Figure 2
Western blot analysis of PADI4 expression in tumor cell lines, tumors and corresponding healthy tissues. 
Extracts were fractioned by electrophoresis and probed with anti-PADI4 antibody. PADI4 immunosignals (67 kDa) were 
detected in malignant tissues, tumor cell lines and some healthy tissues. Densities of the signals were significantly stronger in 
tumor tissues than in the corresponding healthy controls. Lanes 1–2, gastric adenocarcinomas and corresponding healthy tis-
sues; lanes 3–4 lung adenocarcinomas and corresponding healthy tissues; lanes 5–6, hepatocellular carcinomas and correspond-
ing healthy tissues; lanes 7–8, esophageal squamous cell cancers and corresponding healthy tissues; lanes 9–10, breast cancers 
and corresponding healthy tissues; lanes 11–12, breast fibroadenomas and corresponding healthy tissues; and lanes 13–15, 
A549, SKOV3 and U937 cells, respectively.BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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malignancies. Plasma cAT expression was not considera-
bly altered in patients with breast fibroadenomas, acute
pancreatitis, chronic nephritis and cervicitis, and dis-
played slightly diminished levels in patients with chronic
gastritis and acute appendicitis when compared to those
of healthy control subjects. The cAT content was higher in
samples from patients with thyroid adenomas, hepatitis A
and B, liver cirrhosis and pulmonitis compared to healthy
controls (see Figure 4). cAT levels associated significantly
with PADI4 levels in patients with hepatocellular carcino-
mas, lung cancer, ovarian cancer, endometrial carcinomas
and thyroid adenomas (p < 0.01). In addition, cAT levels
clearly associated with CEA levels in the blood of patients
with breast carcinomas (p = 0.032), CA199 levels in those
with gastric cancer (p = 0.025), CEA levels in those with
pancreatic cancer (p = 0.05), CA125 levels in those with
ovarian cancer (p = 0.03), CEA levels in those with blad-
der cancer (p = 0.016), CEA in those with renal cell carci-
nomas (p = 0.046), and PSA in those with prostate cancer
(p = 0.028). PADI4 levels also significantly associated
with CEA levels in patients with gastric cancer (p = 0.05)
and prostate cancer (p = 0.028).
Discussion
We previously detected intense PADI4 expression in a
variety of adenocarcinomas, but expression was absent in
normal, healthy tissues [3]. In the current study, we dem-
onstrated the presence of extensive PADI4 expression in
malignant tissues, but not in most benign and non-tumor
tissues. Furthermore, quantitative PCR and western blot
PADI4 transcription levels in tumors and corresponding healthy tissues by TaqMan quantitative PCR Figure 3
PADI4 transcription levels in tumors and corresponding healthy tissues by TaqMan quantitative PCR. cDNA 
templates were synthesized using an equivalent amount of total RNA for each sample. Lanes 1–2, PADI4 mRNA levels in gas-
tric adenocarcinomas and corresponding healthy tissues; lanes 3–4, lung adenocarcinomas and corresponding healthy tissues; 
lanes 5–6, hepatocellular carcinomas and corresponding healthy tissues; lanes 7–8, esophageal squamous cancer cells and cor-
responding healthy tissues; lanes 9–10, breast cancer cells and corresponding healthy tissues; and lanes 11–12, breast fibroade-
nomas and corresponding healthy tissues.BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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analysis revealed significantly higher PADI4 mRNA and
protein levels in malignant tissues compared to surround-
ing healthy tissues, which were consistent with immuno-
histochemical results. These findings indicated that
PADI4 expression was increased in malignancies at both
the transcriptional and translational levels. Additionally,
PADI4 expression was detected by western blot in cul-
tured A549, SKOV3 and U937 cancer cell lines. PADI4
expression was also detected by Abcam in cultured tumor
cells such as HeLa, Jurkat, A431, HEK293, and HepG2
cells http://www.abcam.com/index.html?datash
eet=38772. These results further confirmed PADI4 expres-
sion in various tumor types.
Here, relatively high PADI4 expression was observed in
breast fibroadenomas and thyroid adenomas by immu-
Levels of PADI4 and cAT in plasma of patients with various tumors Figure 4
Levels of PADI4 and cAT in plasma of patients with various tumors. Plasma samples are listed as the followings: lane 
1–4 breast carcinoma (n = 112), after receiving surgery (n = 86), breast fibroadenomas controls (n = 30), and health controls 
(n = 42); 5–10 hepatocellular carcinomas (n = 77), after receiving surgery (n = 24), hepatitis A controls (n = 28), hepatitis B 
controls (n = 14), liver cirrhosis controls (n = 27), and healthy controls (n = 42); 11–14 lung cancer (n = 127), after receiving 
surgery (n = 24), pulmonitis controls (n = 48), and healthy controls (n = 31); 15, 16 esophageal carcinomas (n = 64) and healthy 
controls (n = 44); 17–21 gastric cancer (n = 94), after receiving surgery (n = 43), chronic gastritis controls (n = 31), acute 
appendicitis controls (n = 22), and healthy controls (n = 38); 22–24 colon cancer (n = 21), after receiving surgery (n = 15), and 
healthy controls (n = 17); 25–27 rectal cancer (n = 19), after receiving surgery (n = 28), and healthy controls (n = 17); 28–31 
pancreatic cancer (n = 21), after receiving surgery (n = 6), acute pancreatitis controls (n = 7), and healthy controls (n = 60); 
32–34 ovarian carcinomas (n = 29), after receiving surgery (n = 11), and healthy controls (n = 23); 35, 36 prostate cancer (n = 
18) and healthy controls (n = 23),; 37–39 renal cell carcinomas (n = 19), chronic nephritis controls (n = 11), and healthy con-
trols (n = 60); 40, 41 bladder carcinomas (n = 10) and healthy controls (n = 23); 42–46 cervical cancer (n = 24), endometrial 
carcinomas (n = 15), uterine myomas (n = 34), cervicitis (n = 15), and healthy controls (n = 34); 47–49 thyroid carcinomas (n = 
7), thyroid adenomas (n = 16), and healthy controls (n = 36).BMC Cancer 2009, 9:40 http://www.biomedcentral.com/1471-2407/9/40
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nohistochemistry. Co-localized PADI4 and CD34 expres-
sion in tumors, bone marrow as well as other healthy
tissues suggested that cells expressing PADI4 may have
originated from CD34+ stem cells [3]. As many adenomas
contain more CD34+ cells [9-11], we accordingly
observed extensive expression of the PADI4 enzyme in
these tissues. Smeared expression of PADI4 was also
detected in some non-tumor inflamed tissues such as
rodents, acute gastritis and acute appendicitis. As neu-
trophils, monocytes, and macrophages are all derived
from CD34+ stem cells and infiltrate injured tissues dur-
ing inflammation [12], we expected and were able to
detect PADI4 expression in these inflamed tissues. How-
ever, we note that the enzyme was predominantly located
in tumor cells of malignant tissues.
Compared with healthy control subjects, high PADI4 lev-
els were detected in the blood of patients with malignant
tumors, which was consistent with results obtained by
immunohistochemistry. Plasma PADI4 levels in patients
with malignancies were considerably diminished after
tumor excision surgery, suggesting that PADI4 protein cir-
culates in the blood from corresponding tumor tissues.
High PADI4 content was observed in breast fibroade-
noma and thyroid adenoma samples, consistent with
immunohistochemical results of adenomas. Although
increased PADI4 levels in the blood were demonstrated in
patients with acute pancreatitis and appendicitis, most
patients with non-tumor inflammations, such as chronic
gastritis, chronic nephritis, and cervicitis, did not exhibit
variations in PADI4 levels, suggesting that PADI4 may be
elevated in the blood under conditions of acute but not
chronic inflammation.
High levels of cAT were detected in blood of patients with
malignant tumors. Compared with PADI4 expression in
the malignant tumors, cAT expression appeared to be
more specific to malignant tumors and significantly asso-
ciated with known tumor markers. Antithrombin is a pri-
mary plasma inhibitor of thrombin. By in vitro
incubation, we previously demonstrated that a recom-
binant human PADI4 protein can inactivate the
thrombin-inhibitory activity of human antithrombin III
through citrullination [7]. Because the cAT content in the
plasma declined after tumor excision surgery and was gen-
erally associated with PADI4 levels in the blood, we pro-
pose that the high cAT levels observed in the blood was
due to citrullination of PADI4 in tumor tissues. Sup-
pressed antithrombin III activity and unregulated
thrombin activity have broadly been reported in the
plasma of patients with lung adenocarcinomas, renal cell
carcinomas, breast cancer, malignant melanomas, colon
cancer, pancreatic adenocarcinomas, and larynx squa-
mous cell carcinomas [13-16]. Thrombin activity can pro-
mote angiogenesis by increasing transcription of the VEGF
receptor as well as metastasis and hyperplasia by inducing
expression of integrin β 3 [17-19]. In the present study,
high cAT production was specifically and primarily
detected in blood of most malignant tumor types, but not
in blood of benign tumors or non-tumor diseases, sug-
gesting that citrullination of antithrombin may be
involved in promoting carcinogenesis. Therefore, it is for-
mally possible that deregulated thrombin activity drives
thrombin-related tumorigenesis, including malignant
proliferation, invasion and metastasis of tumor cells, as
well as abnormal angiogenesis and fibrin deposition in
tumor tissues.
Many studies have demonstrated the effects of hormone
metabolism on tumorigenesis [20-24]. Using cultured
MCF-7 cells originated from breast cancer, Dong et al.
found that estrogen enhanced PADI4 transcription in an
estrogen receptor-mediated manner [25]. Recently, both
Yao et al. and Li et al. reported that PADI4 repressed
expressions of p53 target genes, including OKL38, p21,
CIP1 and WAF1, by modifying methylated arginine sites
on histones H3 and H4 [26,27]. These modifications con-
sequently interrupt apoptosis and cell cycle progression,
which are primary features of tumorigenic cells. Thus,
these studies suggest that PADI4 plays a role during tum-
origenesis by antagonizing regulation of p53 to tumor
suppressor genes. However, we detected PADI4 primarily
in the cytoplasm of tumor cells in most malignant tissues
as well as citrullinated cytokeratin in certain malignant
tumors [3]. As keratins (notably K5, K7, K8/K18, K19, and
K20) exhibit characteristic expression patterns in human
tumors, and have great importance in immunohisto-
chemical tumor diagnosis of carcinomas [6,28,29], it is
thus possible that citrullination of histones, keratin and
antithrombin are all involved in the tumorigenic process.
Our proposed mechanism for PADI4 in tumorigenesis is
shown in Figure 5.
Conclusion
Compared to benign and non-tumor diseases, many
malignant tumor types exhibited increased PADI4 expres-
sion in tumorous cells. Patients with malignant tumors
also displayed higher plasma levels of both PADI4 and
cAT than patients with benign and non-tumor inflamma-
tions. Plasma levels of cAT and PADI4 in patients with
these malignancies were significantly associated with lev-
els of known tumor markers. Our results implicate the
importance of PADI4 and citrullination in the promotion
of tumorigenesis. However, further study is needed to
understand the exact pathogenic mechanism.
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